UK’s Immunocore begins Phase I trial of uveal melanoma drug IMCgp100

UK-based biotechnology company Immunocore has started its Phase I monotherapy trial of its lead programme, IMCgp100, to treat patients with uveal melanoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news